MT Newswires
Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $768 From $767, Maintains Equalweight Rating
📊
AI Sentiment
Positive
7/10
- Home
- REGN
as of 12-12-2025 3:41pm EST
$736.60
$10.20
-1.37%
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Chart Type:
Time Range:
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 73.9B | IPO Year: | 1991 |
| Target Price: | $795.74 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 41.59 | EPS Growth: | 2.88 |
| 52 Week Low/High: | $476.49 - $790.98 | Next Earning Date: | 10-28-2025 |
| Revenue: | $14,247,800,000 | Revenue Growth: | 2.89% |
| Revenue Growth (this year): | 1.95% | Revenue Growth (next year): | 5.47% |
AI-Powered REGN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.03%
73.03%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Regeneron Pharmaceuticals Inc. (REGN)
Bassler Bonnie L
Sell
Director
REGN Nov 20, 2025
Avg Cost/Share
$750.00
Shares
760
Total Value
$570,000.00
Owned After
1,548
SEC Form 4
Pitofsky Jason
Sell
VP Controller
REGN Nov 7, 2025
Avg Cost/Share
$651.43
Shares
431
Total Value
$280,766.33
Owned After
4,233
SEC Form 4
POON CHRISTINE A
Sell
Director
REGN Oct 29, 2025
Avg Cost/Share
$654.92
Shares
6,500
Total Value
$4,252,745.32
Owned After
8,202
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bassler Bonnie L | REGN | Director | Nov 20, 2025 | Sell | $750.00 | 760 | $570,000.00 | 1,548 | |
| Pitofsky Jason | REGN | VP Controller | Nov 7, 2025 | Sell | $651.43 | 431 | $280,766.33 | 4,233 | |
| POON CHRISTINE A | REGN | Director | Oct 29, 2025 | Sell | $654.92 | 6,500 | $4,252,745.32 | 8,202 |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
PR Newswire
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Regeneron (REGN): Revisiting Valuation After Recent Pullback and 90-Day Share Price Surge
📊
AI Sentiment
Positive
7/10
MT Newswires
Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $745 From $700, Maintains Equalweight Rating
📊
AI Sentiment
Positive
7/10
Barrons.com
Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.
âž–
AI Sentiment
Neutral
5/10
Insider Monkey
​Sanofi (SNY) Completes the Acquisition of Vicebio
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Regeneron Pharmaceuticals' Upcoming Melanoma Data Likely to Look Competitive, RBC Says
📊
AI Sentiment
Positive
7/10
Compare REGN vs Leading Stocks
See how REGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.